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Brain metastases from lung cancer and radiosurgery: 6 
years follow up comparing the RPA, SIR and BSBM patients 
stratification systems
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Objective: to compare three stratiﬁcation systems, the recursive parti-
tioning analysis (RPA), the score index for radiosurgery (SIR) and the 
basic score for brain metastases (BSBM) with a 6 years follow up for 
patients with brain metastases (BM) from lung cancer and treated by 
radiosurgery.
Material and Methods: between February 2000 and December 2005, 
117 patients with 275 brain metastases were treated with a Leksell 
Gamma Knife model C. Median marginal dose was 20 Gy at a median 
50 % isodose. 
Results: median survival (MS) for the entire population is 12 months. 
The survival rate is respectively 50, 33, 12, 10 and 5 % at 1, 2, 3, 4 and 
more than 5 years follow up. Univariate analysis conﬁrms the predic-
tive value of the three systems. MS is 22 months for RPA class I, 12 
months for RPA class II and 2 months for RPA class III, (p < 0,0001). 
According to SIR system, MS is 21, 12, 6 and 3 months for scores 8 to 
10, 5 to 7, 4 and 0 to 3 respectively, (p < 0,0001). According to BSBM 
system, MS is 23, 8, 6 and 2 months for scores 3, 2, 1 and 0 points 
respectively (p < 0,0001).
Conclusions: this comparative study conﬁrms the usefulness of all 
three systems of classiﬁcation to predict the outcome of patients treated 
by radiosurgery. Patients who will beneﬁt the most from RS belong the 
groups RPA class I-II, SIR 5-10 and BSBM 2-3. Patients with BSBM 
score 0, SIR score 0 to 3 and RPA class III have a MS around 3 months 
and are not likely to beneﬁt from radiosurgery.
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Prediction of radiation pneumonitis by dose-volume histogram 
parameters, especially focused on main bronchus
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Background: Recently the risk of radiation pneumonitis (RP) devel-
oping after thoracic irradiation has been reported to depend on the 
irradiated normal lung volume. Although the hilar region has been 
considered to play a key role in developing PR, there is no report about 
dosimetric analysis of the hilar region. Hence, we tried to evaluate 
dosimetric parameters of not only the normal lung tissue but also the 
hilar region. However, because it was difﬁcult to contour the hilar 
region precisely, each main bronchus was employed in stead of the 
hilar region.
Methods: Forty two patients treated with radiation for thoracic ma-
lignancy (lung cancer; 35 patients and mediastinum tumor; 7 patients) 
were retrospectively analyzed. RP was graded according to Common 
Terminology Criteria for Adverse Events version 3.0. Pneumonitic 
event that was not due to infection (proven by blood or respiratory cul-
ture) or tumor progression was scored as radiation pneumonitis within 
3 months after the completion of radiotherapy. Univariate analyses was 
performed the following dosimetric factors generated from the dose-
volume histogram (DVH); mean lung dose (MLD), relative volumes 
of lung receiving more than a threshold dose (Vdose). Each main 
bronchus was deﬁned that the ipsilateral main bronchus was on the side 
containing more than 50% of the PTV and the other main bronchus was 
the contralateral. Mean bronchial dose (MBD) and relative volumes of 
bronchus receiving more than a threshold dose (BrVdose) were gener-
ated from the DVH. Also, potential predictive clinical factors examined 
included age, performance status, chemotherapy, chronic obstructive 
pulmonary disease (COPD), lactate dehydrogenase (LDH), diabetes 
mellitus (DM), hypertension, and Brinkman Index.
Results: Radiotherapy was delivered at 2.0 Gy fractions once daily to a 
total of 34-70 Gy (median 60) with a median follow-up of 7.9 months. 
Of them, 16 patients were received concurrent chemotherapy includ-
ing platinum agents. Grade of 0, 1, 2, 3, and 5 RP was observed in 12, 
15, 11, 3 and 1 patients, respectively. V25 was marginally signiﬁcant 
(p=0.07). On the other hand, ipsilateral BrV15, 20, 25, 30, 60 and 
MBD and contralateral BrV60 were signiﬁcantly associated with the 
development of grade 2 or worse RP (p<0.05). Among them, ipilateral 
BrV60 was most signiﬁcant (p=0.0012). There is no signiﬁcant factor 
among the clinical factors.
Conclusions: The bronchial dosimetric parameters, especially high 
dose, were more useful predictive factors than normal lung tissue dosi-
metric parameters for RP.
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status (PS), gender and extension of disease; new factors= 
expression of EGFR, p53 and cell proliferation defined by Ki67
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The aim of the study was to assess the relation between new factors 
prognostic (expression of EGFR, p53, cell proliferation deﬁned by the 
monoclonal antibody Ki67); classical factors prognostic (performans 
status PS, age, gender, extension of the disease) and survival of patients 
with non-small cell lung cancer stage III and IV.
Patient and Methods: 80 patients were included in this study (male 72 / 
female 8); the median follow up was 15 months.
All tumor samples were formalin-ﬁxed and parafﬁn-embedded. The 
expression of p53, EGFR and Ki 67 were assessed with the use of im-
munohistochemically (IHC). P53 was assessed in 66 cases, EGFR in 73 
cases and cell proliferation deﬁned by the monoclonal antibody Ki67 in 
63 cases. 
Results: The expression of p53 was positive in 20 % of cases, EGFR 
was positive in 58,7 % of cases and cell proliferation in 40 % of cases.
Survival was estimated from the date of ﬁrst cycle of chemotherapy 
using median survival and the Kaplan-Meier survival analysis method. 
for each factor.
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Median survival (month) p
p53 positive 5,03 0,2 
p53 negative 8,2
Ki67 positive 5,3 0,5
Ki67 negative 8,4
EGFR positive 5,3 0,5
EGFR negative 8,2
 Median survival (months) p
PS = 0 11,8 10-6 
PS =1 4,1
PS = 2 1,6
Age less 59 years 5,4 0,9
Age > 59 years 8,2
Female 7,5 0,5
Male 5
N0 9,7 0,008
N1 1,3
N2 8,3
N3 5,2
Conclusions: At this time of the study, there was no relation between 
expression of p53, EGFR, cell proliferation deﬁned by ki67 and surviv-
al. Correlation between PS, nodes extension and survival is conﬁrmed. 
Larger and longer follow-up studies may be needed to determine the 
prognostic role of expression of those new factors in NSCLC.
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Essential role for intensity-modulated radiotherapy (IMRT) in 
post-pneumonectomy mediastinal radiotherapy for stage III-N2 
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Background: Postoperative radiotherapy (PORT) in completely 
resected NSCLC with mediastinal N2 metastases reduces the incidence 
of loco-regional recurrences. The LungART study is an international 
prospective trial to be activated in 2007, randomizing between PORT 
(54Gy) and observation. Although recent reports suggest that PORT 
could improve survival, a previous meta-analysis had suggested 
increased treatment-related mortality, underscoring the need to limit 
doses to the heart and lung using modern treatment techniques. IMRT 
is currently not permitted in the LungART trial due to concerns about 
radiation toxicity arising from an increase in lung volumes exposed to 
low doses. We performed a planning study to determine if dose-con-
straints for critical organs could be achieved in PORT after pneumonec-
tomy.
Methods: Conventional 3D (Eclipse TPS, Varian Medical Systems) 
and IMRT (Helios, VMS) planning techniques were compared in ﬁve 
post-pneumonectomy patients (3 right-sided and 2 left-sided). Both 
limited and extended target volumes were designed according to the 
LungART protocol. The limited target volume consists of the bron-
chial stump, ipsilateral hilus, nodal stations 4 and 7, and in the case of 
left sided tumors also stations 5-6. Extended volumes are used when 
stations 8-9 contain metastasis, and consist of the above, plus the para-
esophageal and pulmonary ligament nodes (stations 8 and 9). All target 
volumes were derived from 4-dimensional (4D) CT scans, incorporat-
ing movement. A 3D margin of 5 mm was added to derive planning 
target volumes (PTV). The planned dose was 54 Gy (1.8 Gy/ fraction), 
using the following constraints: maximum spinal cord dose 45 Gy; 
maximum dose of 35 Gy to ≤30% of the cardiac volume; maximum 
dose of 20 Gy to ≤15% of the lung volume. 
Results: For the limited PTVs, critical organ constraints were met in 
all cases for both conventional radiotherapy and IMRT. For extended 
PTVs, critical organ constraints could only be met using IMRT (Figure 
1). This could be achieved without increasing low dose lung volumes 
(V5). Using conventional techniques for the extended target volumes, 
cardiac doses signiﬁcantly exceeded the speciﬁed constraints.
Conclusions: The use of IMRT appears essential to reduce cardiac 
doses in patients whose PORT volumes include nodal stations 8 and 
9. The decision to exclude IMRT in the forthcoming LungART trial 
should be revised. Planning data on the beneﬁts of respiration-gated 
IMRT delivery for these patients will be available at the time of the 
meeting.
Figure 1: Dose levels (mean percentage in 5 patients) using either convention-
al radiotherapy or IMRT, in limited and extended target volumes. The maximal 
spinal dose was below 45Gy. Error bars represent minimum and maximum 
values.
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Occurrence of brain metastases in locally advanced NSCLC 
treated with radical radiotherapy (RT)
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Occurrence of brain metastases (BM) is a major problem in NSCLC. 
To evaluate the inﬂuence on survival in locally advanced NSCLC 
treated with radical RT, a retrospective analysis was performed of the 
patients treated at our institution. 
Methods: From June 1995 to Feb. 2005 207 patients with non-resect-
able NSCLC stage IIB-IIIAB received radical 3-D conformal RT with 
a planned dose ≥60Gy/30 F. Data on BM were retrospectively obtained 
from the patient ﬁles. End points were occurrence of BM and survival. 
Min. follow-up was 24 months. 
